ImmunityBio, Inc., founded in 2014, operates in the biotechnology, pharmaceuticals, and healthcare sectors, developing innovative treatments for cancer and infectious diseases by empowering the immune system through living biological technologies.
The company's technical domains include natural killer cell platform, genomics, proteomics, monoclonal antibodies, fusion proteins, vaccines, and both autologous and allogeneic cell therapies. Its lead immunotherapy product, ANKTIVA® (N-803), is indicated for BCG-unresponsive non-muscle invasive bladder cancer and holds FDA Breakthrough Therapy designation.
ImmunityBio has 27 clinical trials ongoing across 13 indications, reflecting a broad research scope. The organization emphasizes a patient-first culture with a focus on patient quality of life.
